Kidney Disease, Corporate Finance


Neose Technologies Inc.

in
Neose Technologies Inc. announced that on March 12, 2008, it has entered into a Commercial Insurance Premium Finance and Security Agreement with Cananwill Inc. to finance the insurance policy premiums due on certain insurance policies of the Company. The amount financed under the Finance Agreement is $370,622.96 and, pursuant to its terms, the Company is required to make a payment of $34,391.04 during each of the 11 months beginning on March 15, 2008 and ending on January 15, 2009.

Angiotech Pharmaceuticals Inc

in
Angiotech Pharmaceuticals Inc. announced the filing of its audited consolidated financial statements and Management's Discussion and Analysis for the year ended December 31, 2007 and the restatement of its audited consolidated financial statements for the year ended December 31, 2006. For the year ended December 31, 2007, the Company's net loss according to GAAP was $65.9 million, as compared to $59.4 million reported in the preliminary results announced on February 14, 2008.

Neose Technologies Inc.

in
Neose Technologies Inc. announced that on March 12, 2008, it has entered into a Commercial Insurance Premium Finance and Security Agreement with Cananwill Inc. to finance the insurance policy premiums due on certain insurance policies of the Company.

Neose Technologies, Inc.

in
Neose Technologies, Inc. announced that it has received notice from The NASDAQ Stock Market LLC stating that for 30 consecutive business days the bid price for the Company's common stock has closed below the minimum $1.00 per share required by Marketplace Rule 4450(a)(5) for continued listing on the NASDAQ Global Market. As a result, Neose no longer meets NASDAQ’s continued listing criteria and has 180 calendar days, or until August 18, 2008, to regain compliance.

Fresenius Medical Care

in
Fresenius Medical Care AG (FMC) said fourth-quarter net income rose 30% to $197 million, slightly ahead of consensus estimates. Quarterly revenue grew 9% to $2.569 billion, also slightly above analysts' expectations, which were for $2.533 billion according to the survey. Chief Executive Officer Ulf Schneider said that Fresenius SE is also eyeing acquisitions for up to $441 million.

Baxter International Inc

in
The Board of Directors of Baxter International Inc. declared a quarterly dividend of $0.2175 per share of Baxter common stock. This quarterly dividend is payable on April 1, 2008 to shareholders of record as of March 10, 2008.
 

Nephros, Inc.

in

Amgen Inc.

in
Amgen Inc. announced offers to exchange any and all of its $2,000,000,000 Senior Floating Rate Notes due 2008 for an equal amount of new Senior Floating Rate Notes due 2008, any and all of its $1,100,000,000 5.85% Senior Notes due 2017 for an equal amount

Syndicate content